Harry Rein, Partner Emeritus, Foundation Medical Partners, where he is primarily focused on investing in medical devices. Mr. Rein served for 15 years as the Founder and Managing General Partner of Canaan Partners. In addition to his role as the managing general partner at Canaan Partners, Mr. Rein was responsible for Canaan's Life Sciences Investment Practice. Prior to Canaan Partners, for four years he was President and CEO of GE Venture Capital Corporation. Mr. Rein has extensive experience with small and mid-sized companies, including the supervision of all investments made by GE Venture Capital during his tenure as president. Mr. Rein joined the General Electric Company ("GE") in 1979 and directed several of GE's lighting businesses as general manager before joining the venture capital subsidiary. He has also worked for Transaction Systems, Inc., a strategic consulting firm, as a Vice President; with Gulf Oil Corporation as Director of Corporate Planning; and with Polaroid Corporation in several manufacturing positions. Mr. Rein has served on the boards of directors of over 20 public and private entrepreneurial companies, including: Cell Pathways, OraPharma (acquired by Johnson & Johnson), National MD (acquired by GE), OmniSonics, GenVec (NASDAQ: GNVC), CardioNet (NASDAQ: BEAT) and Spine Wave, and was an investor in Praecis Pharmaceuticals (NASDAQ: PRCS). Currently, Mr. Rein serves on the Board of Directors of Anadigics (NASDAQ: ANAD), IlluminOss Medical and Spine Wave. Previously, Mr. Rein was a member of the Board of Directors of the National Venture Capital Association ("NVCA") and was a recipient of the 2002 NVCA Outstanding Service Award. Mr. Rein also serves as a Trustee of the Cleveland Clinic, and is a member of the Clinic's Research and Education, Finance, and Emerging Businesses committees. Mr. Rein is Chairman of the Industrial Advisory Board of Cleveland Clinic Innovations. He also serves as a Trustee of the University of Virginia Darden School of Business Foundation, where he is a member of the Executive Committee and Chairman of the Investment Committee. Mr. Rein attended Emory University and Oglethorpe College (1968) and holds an M.B.A. from the Darden School at the University of Virginia (1973).
Brian Canann, Managing Director, NaviMed Capital, a Washington, DC based venture capital firm focused on revenue-stage healthcare investments. Prior to co-founding NaviMed Capital, he was a healthcare investment professional at The Carlyle Group.
He also led the global marketing effort for the Endeavor drug-eluting stent development program at Medtronic. Mr. Canann held various strategic planning and global product management positions in the critical care division of Edwards Lifesciences, the global leader in heart valves and hemodynamic monitoring. He was also a CPA in the Boston office of Price Waterhouse.
Mr. Canann is on the Board of Directors of Elenza. He is a Board Observer of AqueSys and PixelOptics. He previously served on the Board of Directors of Carefx (sold to Harris), the HealthCentral Network and Primary Health (sold to PacificSource Health Plans) and as a Board Observer of Endius (sold to Zimmer). He holds a M.S. and a B.S. on accounting from Brigham Young University and an M.B.A. from Harvard Business School.
Roy Davis, was President, Johnson & Johnson Development Corporation (JJDC) and Vice President, Corporate Development, Johnson & Johnson, from January of 2008 until his retirement from J&J on January 1, 2012. In this role ,he was responsible for the management of JJDC , the Johnson & Johnson wholly owned ventures group, various corporate business development functions as well as the creation and management of Red Script Ventures,LLC (J&J's business accelerator). From September, 2003 until the end of 2007, Mr. Davis held the positions of Company Group Chairman, Johnson & Johnson and Worldwide Franchise Chairman, Ortho Clinical Diagnostics with responsibilities for Ortho Clinical Diagnostics, Inc., Veridex LLC, and Therakos, Inc. He was also a member of the Medical Devices & Diagnostics Group Operating Committee during this time. Prior to being named Company Group Chairman, Mr. Davis was named Group President, Therakos, Inc., Virco BVBA, Veridex, LLC, and Ortho Clinical Diagnostics, Inc., Advanced Research, New Technology, and New Market Development. From 1994 to 1999, Mr. Davis held the position of Vice President, Business Development and Strategic Planning for Ortho Diagnostic Systems worldwide, and later the combined Ortho Clinical Diagnostics, Inc. In 2000, he was named Group Vice President, Ortho Clinical Diagnostics, Inc., with responsibility for new business development and the newly formed Advanced Diagnostic Systems. Mr. Davis assumed additional responsibilities as President of Advanced Diagnostic Systems and Therakos, Inc., in July 2001. He subsequently was named President, Virco, BVBA, in September 2002 and he was named Chairman of the Joint Pharmaceutical, Diagnostic Virco Supervisory Board. Mr. Davis joined Johnson & Johnson in 1984 in the marketing department of Ortho Diagnostic Systems, Inc. In late 1988, Mr. Davis was named Managing Director of Ortho Diagnostic Systems, Northern Europe, with responsibility for the United Kingdom, Norway, Denmark, Sweden, Finland, and Ireland. In 1990, Mr. Davis was named President, Ortho Diagnostic Systems of Japan. In 1992, he was appointed Vice President, General Manager for Ortho Diagnostic Systems, United States, Canada, Latin America, and Export. Prior to joining Johnson & Johnson, Mr. Davis held progressively more responsible marketing positions with Warner-Lambert Company and Genetic Systems Corp. as well as management positions in the clinical laboratory industry. Mr. Davis received a Bachelor of Science from the State University of New York and a Master of Science from Rensselaer Polytechnic Institute.
Dr. Firlik joined Foundation Medical Partners in 2005 to concentrate on medical device and biopharmaceutical investments. Prior to Foundation, he was a venture partner at Sprout Group and a managing director of its healthcare technology spinout, New Leaf Venture Partners. Previously, he was a principal at Canaan Partners. Dr. Firlik has led investments and served on the board of directors of many early stage companies. He is a co-founder and inventor of the core technology platform of Northstar Neuroscience (Nasdaq: NSTR), a medical device company that is currently in clinical trials of a neuromodulation technology. Dr. Firlik is the Chairman of NovaVision, a medical therapeutics firm focusing on neuroplasticity for visual disorders. He currently serves on the board of directors of NeuroVista, SpineWave, BridgePoint Medical, Vertos, Visiogen, SetPoint Medical and Intelect Medical. Dr. Firlik is a member of the Cornell University Council. He studied biology at Cornell University and Oxford University, received his MBA from the Katz Graduate School of Business at the University of Pittsburgh, and his MD from Cornell University Medical College. Dr. Firlik is a board certified neurosurgeon and has published numerous scientific articles in the field.
Adele Gulfo is Regional President, of Latin America in Pfizer's Emerging Markets Business Unit In this capacity, she leads a team of over 4,000 colleagues operating across more than 23 countries. In 2011, Pfizer Latin America achieved US $3 billion in revenue and has become the largest revenue generator within the Emerging Markets Business Unit. Previously, Adele served as President and General Manager of Pfizer's U.S. Primary Care Business Unit, which included the managed markets (corporate and government customer) organization for all of Pfizer's Biopharmaceutical Business Units. In 2011, Pfizer's U.S. Primary Care business generated more than US $10 billion in revenue.
Prior to joining Pfizer, Ms. Gulfo was Vice President of Business Development, Innovation and Design for Launch at Astra-Zeneca Pharmaceuticals. In her nine years with the company, she led the multi-billion dollar cardiovascular business, including marketed and emerging products. Among her top achievements, she grew Toprol-XL sales from $200 million to $2 billion and the launched cholesterol-lowering medicine Crestor with a significantly differentiated life-cycle development program, which enabled dramatic growth to over $2 billion in 2009 in a highly competitive market.
The highpoint of her work on Crestor was leading the strategy and execution of the JUPITER trial, the first study of the effects of cholesterol-lowering therapy on people with normal cholesterol levels but elevated hs-CRP levels. The unprecedented results secured a new FDA indication to prevent heart attacks and death in people with no evidence of heart disease, and enabled a 29% growth trajectory for Crestor while other statins were declining.
Before joining AstraZeneca, Ms. Gulfo held positions of increasing responsibility at Warner-Lambert, including senior director of cardiovascular marketing. It was in this role that she launched Lipitor with a scientific-based marketing approach that rapidly propelled the drug to the world's most successful medicine with over $10B in peak year global sales. Prior to launch, Ms. Gulfo developed the market with award-winning medical and public education that helped to establish the significance of lowering cholesterol in preventing and managing heart disease. Partners included the American Heart Association, the National Institutes of Health and leading academic institutions.
Trained as a scientist with experience in both operational and strategic roles, Ms. Gulfo serves as a member of the Board of Directors for the Cleveland Clinic's Global Cardiovascular Innovation Center, a $250 million research and product development consortium established to accelerate the commercialization of cardiovascular products. She also serves as a Director of Volunteers of America – Greater New York, Inc.
Ms. Gulfo has been awarded five U.S. Patents for innovative packaging designed to help patients adhere to their medicines. She frequently speaks at leading industry and business conferences including The Wall Street Journal's Women in the Economy: An Executive Task Force conference, and has been featured in Fortune, Forbes, BusinessWeek, and the Wall Street Journal. She is a member of the C200 – the pre-eminent organization of women business leaders, the National Association of Female Executives, and the Healthcare Businesswomen's Association's Advisory Board. Among many honors, she is especially proud of receiving the 2012 C200 Luminary Award for Corporate Entrepreneurship.
Ms. Gulfo holds a bachelor's degree in Biology and Chemistry from Seton Hall University and a Master of Business Administration degree in Marketing from Fairleigh Dickinson University, both with honors. She studied post-graduate microbiology at the University of Medicine and Dentistry of New Jersey.
Andy is the president and CEO of Epocrates, which is largely recognized as the #1 mobile health app trusted by more than 50% of US physicians and over 1 million clinicians. The company creates meaningful engagement between its large, loyal clinician network and select health organizations through relevant and streamlined access to clinical information. Andy joined the company in April 2012, bringing more than 20 years of healthcare IT experience and leadership to the Company.
His career history includes Carefx, acquired by Harris Corporation in 2011, where he served as chairman and CEO for more than six years. During his tenure, Carefx grew from a small startup to a market leader in clinical interoperability serving hundreds of hospitals around the world. Previously, Andy held senior management positions at WebMD and QuadraMed Corporation. He also currently serves on the board of directors for ABILITY Network Inc.
Keith Kerman, MD is an Operating Partner and Senior Advisor with The Riverside Company, a global private equity firm focused on investing in growth businesses valued at up to $250 million. Dr. Kerman joined Riverside in 2012 and focuses his activity on the firm's healthcare activity. He has 20 years of experience in private equity and operating roles, and has been an executive, investor, and board member in a broad range of healthcare related businesses and organizations.
Prior to joining Riverside, Dr. Kerman was a Managing Director and led the healthcare practice at Primus Capital Funds, a growth equity and middle market buyout firm, and was previously a General Partner with Morgenthaler Ventures. Previously, Dr. Kerman was an operating executive at U.S. Healthcare, where he was president of the company's subsidiary providing managed care services to self-funded health plans. Dr. Kerman was a Robert Wood Johnson Foundation Clinical Scholar at the University of Pennsylvania, a member of the clinical faculty at the Hospital of the University of Pennsylvania, and was a Senior Fellow at the Leonard Davis Institute for Health Economics at The Wharton School. He has an AB and an MD from Brown University, and an MBA from The Wharton School of the University of Pennsylvania.
Dr. Kerman currently serves on the Board of Directors of AxioMed Spine Corporation, Physicians Pharmacy Alliance, and IDOC. He also serves on the worldwide Board of Directors of the Healthcare Information Management Systems Society (HIMSS), is a member of the Cleveland Clinic Innovations Advisory Board, and is Chairman of the Advisory Board of the Cleveland Clinic's Global Cardiology Innovation Center.
John Koski is a Managing Director and Co-heads the Healthcare Practice at Allen & Company. Dr. Koski focuses primarily on the healthcare services and healthcare information technology sectors. Prior to joining Allen in 2005, he had been a Resident in Orthopedic Surgery at the Hospital for Special Surgery in New York City. Previously, he was an Associate in the corporate development department at Amgen. John is a graduate of Harvard College where he received an A.B. in Biology, summa cum laude. He subsequently received an MD with honors from the Yale University School of Medicine and an MBA from Harvard Business School.
Steven Lindseth, CEO, co-founded YouBeauty.com with Dr. Roizen and Dr. Oz. Steve has had a 30 year career starting and building health-related technology businesses. Steve serves on a number of boards including Explorys, Imagescan, Intellis, Healthprize and the Clinic’s Innovation Advisory Board. Mr. Lindseth founded Axentis, Inc, a leading venture backed provider of enterprise software serving the governance, risk and compliance market, where he served as Chairman. Prior to Axentis he founded and served as Chief Executive Officer and then Chairman of Complient Corp., a venture-backed, business-process outsourcing company, sold to Cardiac Science, Inc (NASDAQ) in 2003. He was a founding shareholder of Dental Research Corporation, sold to Bausch & Lomb (NYSE) and Thermoscan Inc., sold to The Gillette Company (NYSE). He has raised over $175 million in private equity for the companies he has helped found. Mr. Lindseth holds a Bachelors Degree in Economics from Pitzer College, a member of the Claremont Colleges, Claremont, California.
Jeffery A. McCaulley is President, Global Reconstructive Division at Zimmer since 2008. He has overall responsibility for the Reconstructive Division, including direct responsibility for Global Brand Management, Product Research and Development, Quality, Regulatory Affairs, Clinical Affairs, and Medical Training & Education, as well as Americas Marketing and Sales. Mr. McCaulley has extensive leadership experience in healthcare technologies, including devices, services, software, and informatics. Prior to joining Zimmer, he served as President and Chief Executive Officer of WK Health from 2005 and Vice President and General Manager of the Diabetes Division of Medtronic from 2002. Mr. McCaulley began his career in 1989 with GE Healthcare, where he held positions of increasing responsibility in sales, marketing, and general management, last serving as President and CEO of GE Clinical Services. Mr. McCaulley graduated summa cum laude with a Bachelor of Science in Aerospace Engineering from the University of Cincinnati and received his Executive MBA from the Owen Graduate School of Management at Vanderbilt University.
Doug Morton, PhD, is presently a consultant in the life sciences arena, working with a variety of for-profit and non-profit organizations. From 2003-2006, he was CEO, Southwest Michigan Innovation Center, an incubator/accelerator located in Kalamazoo, MI that provides wet-laboratory space, access to venture funding and business services to emerging companies in the life sciences arena. Since 2006, he has continued his involvement with the Center as a member of its Managing Directors group. Doug spent the majority of his career in the pharmaceutical industry, joining the Upjohn Company as a research scientist in 1973. He remained with the surviving entity through Upjohn's merger with Pharmacia AB (in 1996), the consolidation of Pharmacia & Upjohn with Monsanto (in 2000), and Pharmacia's merger with Pfizer (2003) serving in a series of increasingly significant discovery research management positions. At the time of the Pfizer merger, he was Group Vice President, Technology Acquisitions & Operations for Discovery Research in Pharmacia Corporation. In this position, he was responsible for technology acquisition and operations for worldwide Discovery Research throughout Pharmacia. Doug holds an A.B. degree (chemistry) from Kenyon College and a PhD degree in Organic Chemistry from Columbia University. He completed postdoctoral studies in organic chemistry at Stanford University. Doug has served on the Board of Directors of TissueInformatics, Inc. from May 2003 until the closing of Paradigm Genetics' acquisition of the company in March 2004. He served as a member of the Board of Directors of Icoria, Inc. (formerly Paradigm Genetics, Inc.) since March 2004 until the acquisition of the Company by Clinical Data, Inc. in December 2005. He also served as Interim CEO of Icoria since April 2005 until the close of the acquisition with Clinical Data. Doug is a member of the Industrial Advisory Board of Cleveland Clinic Foundation Innovations. He is also a member of the Scientific Advisory Board and Management Committee of the Southwest Michigan First Life Science Fund and is also chairman of the Scientific Advisory Boards of Hopen Therapeutics and Metabolic Solutions Development. Doug is also a board member of NanoMed Pharmaceuticals, Inc., NephRx Corporation, TCH Pharmaceuticals, Inc., and Tolera Therapeutics, Inc.
Mulligan joined Primus, a Cleveland-based private equity firm, in 1985 from McKinsey & Company, Inc., the international management consulting firm. Mr. Mulligan has served as a Managing Director of Primus since 1987. His previous work experience includes management positions at Deere and Company and First Chicago Corporation. Mr. Mulligan serves as director of several private companies and Universal Electronics, Inc. (NASDAQ: UEIC) and Golf Galaxy (NASDAQ: GGXY). Mr. Mulligan is a Trustee of The Cleveland Clinic Foundation. Mr. Mulligan is also a trustee of Denison University, the Western Reser ve Land Conservancy, and the Institute for Educational Renewal. Mr. Mulligan also served as chairman of the Industrial Advisory Board from 2002-2007. Mr. Mulligan received a B.A. in economics from Denison University and a M.B.A. from the University of Chicago.
John is an experienced healthcare and technology executive who has co-founded several successful start-ups as well as led mature divisions of several large organizations. Prior to Trident, John was president and CEO of CliniComp International, an acute care clinical information system. Previously, he was an operating partner with JP Morgan Partners. As an Operating Partner with JPMP, John held interim operating roles or active board roles with seven portfolio companies: fusionOne, Tidal Software, Narus, Determine Software, Above-All Software, Call Vision and NinthHouse Network.
Before JPMP, John was Regional Vice-President of Strategic Planning and Business Development for the St. Joseph Health System in Northern California. In that role John acquired or started several business including hospitals, home services, physician networks, and related administrative companies. During that time, he built the St. Joseph Health Foundation, a managed care administrator and practice management company for which he served as President.
Today, John serves on the board of PeriGen, TelaDoc and Intellis.
Beckie specializes in early-stage investing in medical devices and diagnostics at Versant. Beckie's career encompasses 23 years of venture capital and operating experience in medical products as an engineer, entrepreneur, corporate executive and investor. Before co-founding Versant, Beckie was a general partner at Institutional Venture Partners (IVP). From 1994-1996, Beckie served as Senior Vice President at Chiron Diagnostics, a division of Chiron Corporation, where she had responsibility for the $200 million Critical Care business unit. In addition, Beckie was Vice President of Business Development where she led numerous deals in support of Chiron Diagnostics business and technology objectives. Prior to that, she was a co-founder and Vice President at Egis, an IVP portfolio company, and held senior management positions in operations and finance at Lifescan, a Johnson & Johnson Company. During her seven-year term at Lifescan, the company grew from an early-stage venture-funded company to a worldwide market leader in diabetes diagnostics. Beckie has served as a director of ProoDuct Health (sold), Appriva Medical (sold), Quantum Dot (sold), and Coalescent (sold), and currently serves as a director for NeoGuide, Myocor, Intuity Medical, Liposonix, Benvenue, and Spiration. In addition, Beckie serves as an advisor to The Innovation Factory, a medical devices incubator. Beckie holds a BS in Chemical Engineering from Cornell University.
Steve is a Managing Director in Novartis Venture Fund's Cambridge, MA office.
Steve focuses on both medical device and bio/pharma investments for the fund. He brings significant operating and venture capital experience to Novartis' investing efforts. Steve joined the Fund in 2006 as a Managing Director. He has led the investments and serves/d on the board of the following companies : Ablation Frontiers (acquired by Medtronic), Autonomic Technologies Inc., Portaero, Sonitus Medical, and Visiogen (acquired by Abbott).
Prior to Novartis, Steve was at Prism Venture Partners, where he focused on medical devices and served on the boards of iScience Interventional, and Sensitech (acquired by Carrier/UTX). Prior to Prism, Steve was a Kauffman Fellow with Mid-Atlantic Venture Funds. He started his career as an entrepreneur and CEO, raising angel funds to buy the assets of a defunct distribution business out of bankruptcy, and then rebuilt the business over the next five years.
Steve holds an MBA with distinction from the University of Michigan Business School and a BS in mechanical engineering from Columbia University's School of Engineering and Applied Science. He serves on the University of Michigan Wolverine Venture Fund Advisory Board and on the board of the Family to Family Project.
Glenn was appointed as Science and Technology Advisor to Governor Voinovich in June of 1996 and served in that role for both Governor Voinovich and his successor Governor Taft. Dr. Brown received a B.S. in Chemical Engineering from Penn State University and a PhD in the same discipline from the Case Institute of Technology (now Case Western Reserve University). Dr. Brown was associated with Standard Oil (now BP Amoco) for 33 years. He served as Senior Vice President and Chief Technology Officer (as well as Board Member) with responsibility for research and development, engineering, patenting and licensing, health, safety and environmental affairs, alternate energy, and corporate planning. After retirement from Standard Oil, he spent seven years at Case Western Reserve University. While with the University, Dr. Brown was the first Dean of the combined faculties and Vice Provost of Corporate Research and Technology Transfer. Dr. Brown has served on numerous corporate boards including Central Bank, Society National Bank, Ferro Corporation and Nordson Corporation. He has also served as a trustee of the Cleveland Playhouse Square Foundation (Chair, 1991-1996), The Cleveland Opera, The Botanical Garden of Cleveland, Hawken School, Cleveland Reads (Chair, 1987-1993), the Cleveland Advanced Manufacturing Program, Cleveland Engineering Society, the American Red Cross, Notre Dame College, United Way Services, and the American Chemical Society (Chair, Cleveland Section, 1983).
Duncan McVean, PhD, is a self-employed consultant specializing in manufacturing, pharmaceutics, and quality control as applied to pharmaceuticals. Most recently, he was CEO of Ridgeway BioSciences, a business spin-off of CCFI. At the same time, he was Chairman of the Board of Scanlabs, a health and wellness company of which he was one of the founders. Prior to that, Dr. McVean was employed by Ben Venue Laboratories as Vice President from September 1984 to October 1999. Previously, he had been employed at Merrell-National Laboratories in Product Development and, later, in Quality Control. His final position at Merrell was Director of Quality Control. He left Merrell National Laboratories to become a co-founder of Gentek, Inc, a manufacturer of generic pharmaceuticals. At Gentek, he was responsible for Product Development and for Manufacturing. He next joined Adria Laboratories, Inc. as Manager of Product Development and shortly thereafter became Director of Manufacturing. He earned a B.S. in Pharmacy, an M.S. in Pharmacy, and a PhD in Pharmaceutical Chemistry (Physical) from the University of Michigan , and, later, an MBA (Humanistic Management) from Xavier University of Cincinnati. He is a Registered Pharmacist in Michigan and Ohio.
Bill Sanford, Founder and Chairman of Symark LLC, a private equity, technology commercialization, and business development organization headquartered in Naples, Florida. He is also Executive Founder and retired Chairman of the Board, President, and Chief Executive Officer of Steris Corporation (NYSE:STE), a global leader in infection and contamination prevention systems, products, services, and technologies. Mr. Sanford is an experienced entrepreneur, executive, consultant, investor, and board member with extensive new venture, merger and acquisition, turnaround, senior management, and market development experience. His business career has focused on the development and commercialization of healthcare and scientific products, health services, advanced information systems, and other innovative technology applications. He holds several patents related to medical technology and devices. Mr. Sanford serves as a Board member and Advisor to numerous organizations, including KeyCorp (NYSE:KEY), Greatbatch, Inc. (NYSE:GB), ElectroSonics Medical, Inc., CardinalCommerce, MicroGroup, NanoScale Corporation, NutriJoy, Inc., Cleveland Clinic, Kansas State University Foundation, and several early and growth stage technology companies and investment partnerships. He is founding and past Chairman of BioEnterprise Corporation, Chairman Emeritus of NorTech, past Vice Chairman of Omeris, a charter member of the State of Ohio Technology Action Board, Vice Chairman of the Kansas Bioscience Authority, and a Fellow of the American Institute for Medical and Biological Engineering (AIMBE).
Steve Sullivan MD, a long standing member of the IAB, passed away Thanksgiving Day. He had been living in Abu Dhabi. Steve had been a managing director at Skyline Ventures in San Francisco.
Steve had been enormously helpful to the Clinic over the seven plus years he served on the IAB. As a board member he brought many insights -- as an investor, former clinician at the Brigham, Harvard and Stanford Medical Schools, and as a thoughtful business strategist who had a clear sense for what was likely to occur and importantly what was not likely. He was always prepared and made himself available for the Clinic even while living in the UAE. He had been assisting on a couple of Clinic projects when he was diagnosed earlier this month. He was a good friend and will be truly missed. Our deep sympathies to his wife Jay and their entire family.
Innovations has facilitated several Cleveland Clinic Spin-Offs over the last decade. Click here to see our current portfolio.Read More
The Alliance network strives to realize new opportunities for innovation by gaining a 360-degree perspective on healthcare and its future.Read More